Biotech Values

[DewDiligence]

MNTA/BAX—Identities and patent-expiration dates for M923 & M834:

Although BAX and MNTA have not divulged the identifies of the first two FoB’s in the companies’ collaboration, my guesses (from patent applications and offhand webcast comments) are that M923 and M834 are Humira and Orencia (or vice-versa).

Humira goes off-patent in the US in late 2016; Orencia goes off-patent in the US in 2019.

Craig Wheeler has stated that BAX/MNTA will disclose the identity of each FoB in the collaboration when it begins a phase-1 clinical trial. For M923 (the first compound in the collaboration), this disclosure should come in 2014.